Refine
Has Fulltext
- yes (14)
Is part of the Bibliography
- yes (14)
Document Type
- Journal article (14)
Language
- English (14)
Keywords
- discriminant analysis (2)
- principal component analysis (2)
- ATM (1)
- CD274 (1)
- CD319 (1)
- CS1 (1)
- DNA-PK (1)
- FFPE (1)
- FTIR spectroscopy (1)
- HD (1)
- HER2 conversion (1)
- HER2 targeted therapy (1)
- HER2-low (1)
- Hans algorithm (1)
- Head and neck cancers (1)
- IR (1)
- Lymph2Cx assay (1)
- MTB (1)
- MTX (1)
- NGS (1)
- NSCLC (1)
- PET (1)
- PI3K (1)
- PLAG1 rearrangement (1)
- PTEN (1)
- R-CHOP (1)
- T-cell lymphoma (1)
- antigen loss (1)
- breast cancer (1)
- cancer (1)
- cancer care (1)
- cancer metabolism (1)
- cancers and neoplasms (1)
- case report (1)
- cell death (1)
- cell of origin (1)
- classical Hodgkin lymphoma (1)
- confocal Raman imaging (1)
- diagnostics (1)
- diffuse large B-cell lymphoma (1)
- extramedullary disease (1)
- fibroblast activation protein (1)
- fixation (1)
- fluorescence in situ hybridisation (1)
- formalin (1)
- head and neck cancer (1)
- immune checkpoint blockade (1)
- lipids (1)
- lipoblastoma (1)
- lymphoma (1)
- major histocompatibility complex (1)
- malignant tumors (1)
- molecular diagnostics (1)
- molecular imaging (1)
- monoclonal antibody (1)
- multivariate data analysis (1)
- mutation (1)
- outcomes research (1)
- outreach (1)
- panel-sequencing (1)
- patient access (1)
- pediatric (1)
- plasma cells (1)
- precision oncology (1)
- radiotherapy (1)
- raman spectroscopy (1)
- real world data (1)
- retroperitoneal tumor (1)
- salivary gland neoplasia (1)
- salivary gland tumor (1)
- salivary gland tumors (1)
- salivary glands (1)
- surgical oncology (1)
- target validation (1)
- targeted therapies (1)
- tissue preparation (1)
- trastuzumab (1)
- trastuzumab deruxtecan (1)
Institute
- Pathologisches Institut (14)
- Comprehensive Cancer Center Mainfranken (4)
- Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen (4)
- Medizinische Klinik und Poliklinik II (4)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (3)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Frauenklinik und Poliklinik (1)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (1)
- Kinderklinik und Poliklinik (1)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (1)
High programmed cell death 1 ligand 1 (PD-L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin- and Reed–Sternberg cells (HRSC) have been shown to be associated with favourable response to anti-PD-1 checkpoint inhibition in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In the present study, we investigated baseline 9p24.1 status as well as PD-L1 and major histocompatibility complex (MHC) class I and II protein expression in 82 biopsies from patients with early stage unfavourable cHL treated with anti-PD-1-based first-line treatment in the German Hodgkin Study Group (GHSG) NIVAHL trial (ClinicalTrials.gov Identifier: NCT03004833). All evaluated specimens showed 9p24.1 CNA in HRSC to some extent, but with high intratumoral heterogeneity and an overall smaller range of alterations than reported in advanced-stage or r/r cHL. All but two cases (97%) showed PD-L1 expression by the tumour cells in variable amounts. While MHC-I was rarely expressed in >50% of HRSC, MHC-II expression in >50% of HRSC was found more frequently. No obvious impact of 9p24.1 CNA or PD-L1 and MHC-I/II expression on early response to the highly effective anti-PD-1-based NIVAHL first-line treatment was observed. Further studies evaluating an expanded panel of potential biomarkers are needed to optimally stratify anti-PD-1 first-line cHL treatment.